Other substances

AT-511

An RNA-dependent RNA polymerase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

AT-511 is a free base of a guanine nucleotide analogue (AT-9010) prodrug (AT-527; the terms AT-511 and AT-527 are often used interchangeably). The active metabolite is a known hepatitis C virus RNA-dependent RNA polymerase inhibitor. It was shown to be present in substantial amounts in primary human respiratory tract cells treated with AT-511 and non-human primates which were administered the prodrug. It manifests anti-coronaviral activity in vitro with low cytotoxicity (Good et al., 2021).

AT-511 (AT-527) on DrugBank
AT-511 (AT-527) on PubChem

Synonyms

AT-527; Propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19 RdRpol Small molecule In vitro	Huh-7 cells; Human airway epithelial cells; Male non-naïve cynomolgus monkeys (pharmacokinetics study)	4.92	The compound inhibited SARS-CoV-2 replication in Huh-7 cells with an EC90 of 0.47 µM and SI of >250 and in human airway epithelial (HAE) cells with an EC90 of 0.34 µM and SI of >160. The compound was shown to be metabolized into the active drug in HAE cells and the active drug levels were computed to be of substantial levels in non-human primates which were administered the compound's hemi-sulphate salt.	Feb/08/2021

AI-suggested references

Link	Publication date
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents	Jul/17/2021
A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase	Mar/30/2020
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture	Feb/22/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT05059080	A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study	Active, not recruiting		Jun/15/2021	Mar/14/2022
Alternative id - CV43140\|2021-000627-12 Interventions - Study type - Observational Study results - No Results Available Locations - Instituto Ave Pulmo, Mar Del Plata, Argentina\|Private Practice Dr Jean Benoit Martinot, Erpent, Belgium\|Medif, Gozée, Belgium\|L2IP -Instituto de Pesquisas Clínicas Ltda., Brasilia, DF, Brazil\|Chronos Pesquisa Clinica, Taguatinga, DF, Brazil\|Hospital Agamenon Magalhães, Recife, PE, Brazil\|Conjunto Hospitalar do Mandaqui, Sao Paulo, SP, Brazil\|Aalborg Universitetshospital, Aalborg, Denmark\|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark\|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark\|Praxis am Ebertplatz, Köln, Germany\|CIMAB SA de CV, Torreón, Coahuila, Mexico\|Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, Mexico\|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico\|PanAmerican Clinical Research, Querétaro, Queréaro, Queretaro, Mexico\|Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara, Mexico\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico\|Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal\|Centro Hospitalar de Leiria (CHL), Leiria, Portugal\|Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal\|Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucuresti, Romania\|County Hospital Caracal, Caracal, Romania\|Sibiu Emergency Clinical County Hospital, Sibiu, Romania\|Gazi Universitesi Tip Fakultesi, Ankara, Turkey\|Hacettepe University Medical Faculty, Ankara, Turkey\|Koc University Medical Faculty Hospital, Istanbul, Turkey\|Ege University Medical Faculty, Izmir, Turkey\|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey\|Ankara University Medical Faculty - PPDS, Çankaya, Turkey\|Istanbul University Cerrahpasa Medical Faculty Hospital; Tesvikiye Caddesi No:20, Şi̇şli̇, Turkey\|Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Katerynoslav Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital #13" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|Public Non-Profit Enterprise "City Outpatient Clinic #9" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|CNPE City Clinical Hospital #6 of DCC, Dnipro, Kholm Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council, Dnipro, KIEV Governorate, Ukraine\|CNPE Ivano-Frankivsk Regional Centre of Phthisiology and Pulmonology of IFRC, Ivano Frankivsk, KIEV Governorate, Ukraine\|Medical Center LLC "Harmony of Beauty", Kyiv, KIEV Governorate, Ukraine\|CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv, KIEV Governorate, Ukraine\|Medical Center of LLC Preventclinic, Kyiv, KIEV Governorate, Ukraine\|Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine\|Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv, KIEV Governorate, Ukraine\|Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Podolia Governorate, Ukraine\|Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia, Tavria Okruha, Ukraine\|Private Enterprise Private Manufacturing Company Acinus, Kirovograd, Ukraine Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 73 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - COVID-19 Symptoms Assessment through the COVID-19 Symptom Diary (Items 1-14)\|Dyspnea Symptoms Assessment through the Patient Reported Outcomes Measurement Information System (PROMIS) - Dyspnea Questionnaire\|Respiratory Symptoms Assessment through the St. George's Respiratory Questionnaire (SGRQ)\|Proportion of Participants with COVID-19 Related Medically-Attended Visits\|Proportion of Participants with Death Attributable to Progression of COVID-19\|Proportion of Participants Re-Infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)\|Proportion of Participants with any Post-Treatment Infection\|Frequency of COVID-19 Related Complications\|Proportion of Participants with Adverse Events (AEs) and Serious AEs (SAEs)
NCT04877769	Bronchopulmonary PK of AT-527 (R07496998)	Completed	Phase 1	Apr/25/2021	Aug/31/2021
Alternative id - AT-03A-007 Interventions - Drug: AT-527 Study type - Interventional Study results - No Results Available Locations - Atea Study Site, London, United Kingdom Study designs - Allocation: Non-Randomized\|Intervention Model: Sequential Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 24 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Concentrations of AT-527 in epithelial lining fluid
NCT05126576	Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19	Suspended	Phase 3	Apr/28/2021	Nov/17/2021
Alternative id - CV43043\|2020-005759-18 Interventions - Drug: RO7496998\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Instituto Medico Rio Cuarto, Cordoba, Argentina\|Instituto Ave Pulmo, Mar Del Plata, Argentina\|Clínica Independencia, Munro, Argentina\|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina\|Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, Argentina\|Sanatorio Medico de Diagnostico Y Tratamiento, Santa Fe, Argentina\|Maison Médicale La Brèche, Châtelineau, Belgium\|Private Practice Dr Jean Benoit Martinot, Erpent, Belgium\|Medif, Gozée, Belgium\|L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil\|Chronos Pesquisa Clinica, Taguatinga, DF, Brazil\|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil\|Hospital Agamenon Magalhães, Recife, PE, Brazil\|Hospital Nossa Senhora das Graças, Curitiba, PR, Brazil\|Hospital Erasto Gaertner, Curitiba, PR, Brazil\|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil\|Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, Sao Jose Do Rio Preto, SP, Brazil\|CPQuali Pesquisa Clínica Sao Paulo, Sao Paulo, SP, Brazil\|Institute of Infectious Diseases Emilio Ribas, Sao Paulo, SP, Brazil\|Conjunto Hospitalar do Mandaqui, Sao Paulo, SP, Brazil\|Aalborg Universitetshospital, Aalborg, Denmark\|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark\|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark\|Centre Hospitalier Victor Dupouy, Argenteuil, France\|Hôpital Saint Joseph, Marseille, France\|Hopital Tenon, Paris, France\|Klinikum Chemnitz gGmbH, Chemnitz, Germany\|Universitätsklinikum Frankfurt, Frankfurt, Germany\|Universitätsklinikum Freiburg, Freiburg, Germany\|Praxis am Ebertplatz, Köln, Germany\|ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco, Lombardia, Italy\|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy\|Comprensorio Amedeo Di Savoia Birago Di Vische, Torino, Piemonte, Italy\|Funabashi Central Hospital, Funabashi-Shi, Japan\|Higashiosaka city Medical Center, Higashiosaka-Shi, Japan\|Rinku General Medical Center, Izumisano, Japan\|Sagamihara Kyodo Hospital, Kanagawa, Japan\|Misyuku hospital, Meguro-Ku, Japan\|Nagoya City East Medical Center, Nagoya-Shi Chikusa-Ku, Japan\|Fujita Health University Banbuntane Hotokukai Hospital, Nagoya-shi, Japan\|Tokyo Metropolitan Police Hospital, Nakano-Ku, Japan\|IUHW Narita Hospital, Narita, Japan\|Houjin Syadan Kouhoukai Takagi Hospital, Okawa-Shi, Japan\|Okayama City Hospital, Okayama, Japan\|Ome Municipal General Hospital, Ome-Shi, Japan\|Osaka City General Hospital, Osaka, Japan\|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan\|Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan\|St. Luke's International Hospital, Tokyo, Japan\|Edogawa Medicare Hospital, Tokyo, Japan\|Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan\|JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan\|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan\|National Hospital Organization Kasumigaura Medical Center, Tsuchiurat, Japan\|Mie Prefectural Medical Centre, Yokkaichi, Japan\|CIMAB SA de CV, Torreón, Coahuila, Mexico\|Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, Mexico\|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico\|PanAmerican Clinical Research, Querétaro, Queréaro, Queretaro, Mexico\|Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara, Mexico\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico\|CEPREP; Hospital Universitario, Monterrey, Mexico\|Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal\|Centro Hospitalar de Leiria (CHL), Leiria, Portugal\|Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal\|Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucuresti, Romania\|County Hospital Caracal, Caracal, Romania\|Sibiu Emergency Clinical County Hospital, Sibiu, Romania\|Dr. Victor Babes Clinical Hospital of Pneumophthisiology and Infectious Diseases, Timişoara, Romania\|Dr JM Engelbrecht Trial site, Cape Town, South Africa\|TASK Eden, George, South Africa\|Langeberg Clinical Trials, Kraaifontein, South Africa\|Clinical Projects Research, Worcester, South Africa\|Hôpital Universitaire de Genève (HUG), Genève, Switzerland\|Universitätsspital Zürich, Zürich, Switzerland\|Gazi Universitesi Tip Fakultesi, Ankara, Turkey\|Hacettepe University Medical Faculty, Ankara, Turkey\|Koc University Medical Faculty Hospital, Istanbul, Turkey\|Ege University Medical Faculty, Izmir, Turkey\|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey\|Ankara University Medical Faculty - PPDS, Çankaya, Turkey\|Istanbul University Cerrahpasa Medical Faculty Hospital; Tesvikiye Caddesi No:20, Şi̇şli̇, Turkey\|Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Katerynoslav Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital #13" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|Public Non-Profit Enterprise "City Outpatient Clinic #9" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|CNPE City Clinical Hospital #6 of DCC, Dnipro, Kholm Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council, Dnipro, KIEV Governorate, Ukraine\|CNPE Ivano-Frankivsk Regional Centre of Phthisiology and Pulmonology of IFRC, Ivano Frankivsk, KIEV Governorate, Ukraine\|Private Enterprise Private Manufacture Company "Acinus", diagnostic and treatment center, Kirovograd, KIEV Governorate, Ukraine\|Medical Center LLC "Harmony of Beauty", Kyiv, KIEV Governorate, Ukraine\|CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv, KIEV Governorate, Ukraine\|Medical Center of LLC Preventclinic, Kyiv, KIEV Governorate, Ukraine\|Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine\|Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv, KIEV Governorate, Ukraine\|Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Podolia Governorate, Ukraine\|Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia, Tavria Okruha, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 1386 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)\|Time to Alleviation of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation of COVID-19 Symptoms (43 hours)\|Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms\|Time to Alleviation of Individual Symptoms\|Proportion of Participants Requiring Hospitalization for COVID-19\|Proportion of Participants with Greater than or Equal to 1 COVID-19 Related Medically Attended Visit\|Duration of Fever\|Frequency of COVID-19 Related Complications\|Proportion of Participants with any Post-Treatment Infection\|Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA\|Time to Cessation of SARS-CoV-2 Viral Shedding\|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints\|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA\|Percentage of Participants with Adverse Events (AEs)\|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273 at Specified Timepoints
NCT04709835	Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19	Completed	Phase 2	Feb/03/2021	Oct/13/2021
Alternative id - WV43042 Interventions - Drug: AT-527\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Multiprofile Hospital for Active Treatment Puls AD PPDS, Blagoevgrad, Bulgaria\|Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC, Gabrovo, Bulgaria\|MHAT Dr. Atanas Dafovski AD, Kardzhali, Bulgaria\|Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD, Lovech, Bulgaria\|Medical center Medconsult Pleven OOD, Pleven, Bulgaria\|University Multiprofile Hospital for Active Treatment Sveta Marina Pleven OOD, Pleven, Bulgaria\|Multiprofile Hospital for Active Treatment Plovdiv, Plovdiv, Bulgaria\|MHAT "Sv. Ivan Rilski" - Razgrad AD; Department of pnemology and phthisiatry, Razgrad, Bulgaria\|Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Dr. D. Gramatikov - Ruse, Ruse, Bulgaria\|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria\|Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia, Bulgaria\|Diagnostic Consultative CTR XX Sofia EOOD, Sofia, Bulgaria\|Multiprofile Hospital for Active Treatment (MHAT) - Targovishte, Targovishte, Bulgaria\|Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada\|Hamilton Medical Research Group, Hamilton, Ontario, Canada\|Evangelismos General Hospital of Athens, Athens, Greece\|Sotiria General Hospital of Athens; 3rd Department of Internal Medicine, Athens, Greece\|National and Kapodistrian University of Athens, Athens, Greece\|University General Hospital of Ioannina, Ioannina, Greece\|General State Hospital of Nikaia St Panteleimon, Nikaia Attikis, Greece\|Connolly Hospital, Dublin, Ireland\|Private Practice of Dr Liga Kozlovska, Balvi, Latvia\|RSU Ambulance, Riga, Latvia\|Outpatient Clinic Alma, Rīga, Latvia\|Outpatient Clinic Adoria, Rīga, Latvia\|The Family Physician's Practice of Dr. Maija Kozlovska, Salaspils, Latvia\|M & M Centrs, Ādaži, Latvia\|UAB Inmedica, Kaunas, Lithuania\|JSC Saules Family Health Center, Kaunas, Lithuania\|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania\|Krakowskie Centrum Medyczne Sp. z o.o., Krakow, Poland\|Centrum Medyczne Pulawska SP. z o.o., Piaseczno, Poland\|Centralny Szpital Klinicznty MSWiA w Warszawie, Warszawa, Poland\|Centrum Badań Klinicznych, Wrocław, Poland\|Hospital El Pilar - Grupo Quirónsalud, Esplugues de Llobregat, Barcelona, Spain\|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain\|Hospital Costa del Sol, Marbella, Malaga, Spain\|Hospital Universitario La Paz - PPDS, Barcelona, Spain\|Hospital Universitario Infanta Leonor, Madrid, Spain\|Chapel Street Medical Centre, Ashton-under-Lyne, United Kingdom\|Tower Family Healthcare - Moorgate Primary Care Ce, Bury, United Kingdom\|CPS Research, Glasgow, United Kingdom\|Chelsea and Westminster NHS Trust, London, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 104 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA\|Time to Cessation of SARS-CoV-2 Viral Shedding\|Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA\|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints\|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA\|Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)\|Time to Alleviation of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation of COVID-19 Symptoms (43 hours)\|Duration of Fever\|Frequency of COVID-19 Related Complications\|Time to Alleviation of an Individual Symptom\|Percentage of Participants with Adverse Events (AEs)\|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273
NCT04889040	Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19	Terminated	Phase 3	Apr/28/2021	Nov/17/2021
Alternative id - CV43043\|2020-005759-18 Interventions - Drug: RO7496998\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Instituto Medico Rio Cuarto, Cordoba, Argentina\|Instituto Ave Pulmo, Mar Del Plata, Argentina\|Clínica Independencia, Munro, Argentina\|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina\|Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, Argentina\|Sanatorio Medico de Diagnostico Y Tratamiento, Santa Fe, Argentina\|Maison Médicale La Brèche, Châtelineau, Belgium\|Private Practice Dr Jean Benoit Martinot, Erpent, Belgium\|Medif, Gozée, Belgium\|L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil\|Chronos Pesquisa Clinica, Taguatinga, DF, Brazil\|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil\|Hospital Agamenon Magalhães, Recife, PE, Brazil\|Hospital Nossa Senhora das Graças, Curitiba, PR, Brazil\|Hospital Erasto Gaertner, Curitiba, PR, Brazil\|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil\|Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, Sao Jose Do Rio Preto, SP, Brazil\|CPQuali Pesquisa Clínica Sao Paulo, Sao Paulo, SP, Brazil\|Institute of Infectious Diseases Emilio Ribas, Sao Paulo, SP, Brazil\|Conjunto Hospitalar do Mandaqui, Sao Paulo, SP, Brazil\|Healthy Medical Center SAS, Zipaquirá, Colombia\|Aalborg Universitetshospital, Aalborg, Denmark\|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark\|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark\|Centre Hospitalier Victor Dupouy, Argenteuil, France\|Hôpital Saint Joseph, Marseille, France\|Hopital Tenon, Paris, France\|Klinikum Chemnitz gGmbH, Chemnitz, Germany\|Universitätsklinikum Frankfurt, Frankfurt, Germany\|Universitätsklinikum Freiburg, Freiburg, Germany\|Praxis am Ebertplatz, Köln, Germany\|ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco, Lombardia, Italy\|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy\|Comprensorio Amedeo Di Savoia Birago Di Vische, Torino, Piemonte, Italy\|Funabashi Central Hospital, Funabashi-Shi, Japan\|Higashiosaka city Medical Center, Higashiosaka-Shi, Japan\|Rinku General Medical Center, Izumisano, Japan\|Sagamihara Kyodo Hospital, Kanagawa, Japan\|Misyuku hospital, Meguro-Ku, Japan\|Nagoya City East Medical Center, Nagoya-Shi Chikusa-Ku, Japan\|Fujita Health University Banbuntane Hotokukai Hospital, Nagoya-shi, Japan\|Tokyo Metropolitan Police Hospital, Nakano-Ku, Japan\|IUHW Narita Hospital, Narita, Japan\|Houjin Syadan Kouhoukai Takagi Hospital, Okawa-Shi, Japan\|Okayama City Hospital, Okayama, Japan\|Ome Municipal General Hospital, Ome-Shi, Japan\|Osaka City General Hospital, Osaka, Japan\|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan\|Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan\|St. Luke's International Hospital, Tokyo, Japan\|Edogawa Medicare Hospital, Tokyo, Japan\|Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan\|JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan\|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan\|National Hospital Organization Kasumigaura Medical Center, Tsuchiurat, Japan\|Mie Prefectural Medical Centre, Yokkaichi, Japan\|CIMAB SA de CV, Torreón, Coahuila, Mexico\|Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, Mexico\|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico\|PanAmerican Clinical Research, Querétaro, Queréaro, Queretaro, Mexico\|Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara, Mexico\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico\|CEPREP; Hospital Universitario, Monterrey, Mexico\|Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal\|Centro Hospitalar de Leiria (CHL), Leiria, Portugal\|Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal\|Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucuresti, Romania\|County Hospital Caracal, Caracal, Romania\|Sibiu Emergency Clinical County Hospital, Sibiu, Romania\|Dr. Victor Babes Clinical Hospital of Pneumophthisiology and Infectious Diseases, Timişoara, Romania\|Dr JM Engelbrecht Trial site, Cape Town, South Africa\|TASK Eden, George, South Africa\|Langeberg Clinical Trials, Kraaifontein, South Africa\|Clinical Projects Research, Worcester, South Africa\|Hôpital Universitaire de Genève (HUG), Genève, Switzerland\|Universitätsspital Zürich, Zürich, Switzerland\|Gazi Universitesi Tip Fakultesi, Ankara, Turkey\|Hacettepe University Medical Faculty, Ankara, Turkey\|Koc University Medical Faculty Hospital, Istanbul, Turkey\|Ege University Medical Faculty, Izmir, Turkey\|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey\|Ankara University Medical Faculty - PPDS, Çankaya, Turkey\|Istanbul University Cerrahpasa Medical Faculty Hospital; Tesvikiye Caddesi No:20, Şi̇şli̇, Turkey\|Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Katerynoslav Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital #13" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|Public Non-Profit Enterprise "City Outpatient Clinic #9" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine\|CNPE City Clinical Hospital #6 of DCC, Dnipro, Kholm Governorate, Ukraine\|Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council, Dnipro, KIEV Governorate, Ukraine\|CNPE Ivano-Frankivsk Regional Centre of Phthisiology and Pulmonology of IFRC, Ivano Frankivsk, KIEV Governorate, Ukraine\|Private Enterprise Private Manufacture Company "Acinus", diagnostic and treatment center, Kirovograd, KIEV Governorate, Ukraine\|Medical Center LLC "Harmony of Beauty", Kyiv, KIEV Governorate, Ukraine\|CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv, KIEV Governorate, Ukraine\|Medical Center of LLC Preventclinic, Kyiv, KIEV Governorate, Ukraine\|Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine\|Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv, KIEV Governorate, Ukraine\|Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Podolia Governorate, Ukraine\|Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia, Tavria Okruha, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 1386 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)\|Time to Alleviation of COVID-19 Symptoms (21.5 hours)\|Time to Alleviation of COVID-19 Symptoms (43 hours)\|Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms\|Time to Alleviation of Individual Symptoms\|Proportion of Participants Requiring Hospitalization for COVID-19\|Proportion of Participants with Greater than or Equal to 1 COVID-19 Related Medically Attended Visit\|Duration of Fever\|Frequency of COVID-19 Related Complications\|Proportion of Participants with any Post-Treatment Infection\|Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA\|Time to Cessation of SARS-CoV-2 Viral Shedding\|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints\|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA\|Percentage of Participants with Adverse Events (AEs)\|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273 at Specified Timepoints
NCT04396106	Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting	Recruiting	Phase 2	May/26/2020	Aug/01/2022
Alternative id - AT-03A-001 Interventions - Drug: AT-527\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Atea Study Site, Scottsdale, Arizona, United States\|Atea Study Site, Davis, California, United States\|Atea Study Site, Los Angeles, California, United States\|Atea Study Site, Washington, District of Columbia, United States\|Atea Study Site, Orlando, Florida, United States\|Atea Study Site, Atlanta, Georgia, United States\|Atea Study Site, Chicago, Illinois, United States\|Atea Study Site, Chicago, Illinois, United States\|Atea Study Site, Boston, Massachusetts, United States\|Atea Study Site, Butte, Montana, United States\|Atea Study Site, Charlotte, North Carolina, United States\|Atea Study Site, Cincinnati, Ohio, United States\|Atea Study Site, Columbus, Ohio, United States\|Atea Study Site, Charleston, South Carolina, United States\|Atea Study Site, Columbia, South Carolina, United States\|Atea Study Site, Rosario, Argentina\|Atea Study Site, Vicente Lopez, Argentina\|Atea Study Site, Brussels, Belgium\|Atea Study Site, Mechelen, Belgium\|Atea Study Site, Belo Horizonte, Brazil\|Atea Study Site, Brasília, Brazil\|Atea Study Site, Campo Largo, Brazil\|Atea Study Site, Porto Alegre, Brazil\|Atea Study Site, São Paulo, Brazil\|Atea Study Site, Cairo, Egypt\|Atea Study Site, Chisinau, Moldova, Republic of\|Atea Study Site, Bucharest, Romania\|Atea Study Site, Bloemfontein, South Africa\|Atea Study Site, Cape Town, South Africa\|Atea Study Site, Centurion, South Africa\|Atea Study Site, George, South Africa\|Atea Study Site, Worcester, South Africa\|Atea Study Site, Barcelona, Spain\|Atea Study Site, Madrid, Spain\|Atea Study Site, Pozuelo De Alarcón, Spain\|Atea Study Site, Brovary, Ukraine\|Atea Study Site, Kyiv, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 190 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Part A: Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.\|Part B: Change from baseline in amount of SARS-CoV-2 virus RNA\|Parts A and B: Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events\|Part A: Change from baseline in amount of SARS-CoV-2 virus RNA

Export (.csv)